Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

After layoffs at Recursion, the company’s CEO writes about taking inspiration from an unexpected source: “The Art of Racing ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Kevin Roose and Casey Newton are the hosts of The Times’s “Hard Fork” podcast. They recorded this conversation (which has ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Based on its latest expense profile and business plan, after cutting its staff, Recursion said it now expects its projected cash runway to extend into the fourth quarter of 2027. Recursion will pay ...

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other best ...

This important study demonstrates the significance of incorporating biological constraints in training neural networks to develop models that make accurate predictions under novel conditions. By ...

We develop and quantify a novel growth theory in which economic activity endogenously shifts from material production to quality improvements. Consumers derive utility from goods with differing ...